Laurus Labs Acquires Majority Stake in Galenvs Sciences
The $3.75 million deal grants the CDMO firm new DNA and RNA manufacturing capabilities in Canada and India.
Updated on Oct. 29, 2026 in Healthcare
Live Poll
Do you believe large pharmaceutical companies acquiring smaller biotech startups benefits the healthcare market?
Laurus Labs signed a definitive agreement to acquire a 60% stake in Canadian biotechnology firm Galenvs Sciences. The $3.75 million investment aims to enhance oligonucleotide development capabilities for the Hyderabad-based company.
Why it matters
The deal allows Laurus Labs to integrate specialized magnetic nanoparticle and DNA/RNA technologies into its contract development and manufacturing organization (CDMO) services. This move scales its research and production footprint across both North American and Indian markets.
Laurus Labs is investing $3.75 million to secure a 60% stake in Galenvs Sciences, which carries a $3.5 million pre-money valuation. The deal includes a primary cash infusion of $2.75 million to support global expansion efforts.
The players
Laurus Labs
A research-driven pharmaceutical and CDMO company based in Hyderabad with global operations.
Galenvs Sciences
A Canadian biotechnology firm specializing in magnetic nanoparticles and advanced DNA/RNA research technologies.
The details
Laurus Labs intends to leverage this partnership to bolster its oligonucleotide development and manufacturing offerings. The strategy includes expanding specialized scientific talent in Montréal while concurrently scaling manufacturing infrastructure in India. These efforts aim to broaden the company's service portfolio within the highly competitive CDMO sector.
Timeline
October 29, 2026: Laurus Labs announced the acquisition agreement to the bourses.
Market Landscape
This acquisition mirrors a broader trend where CDMOs are aggressively seeking to internalize specialized genetic-material production capabilities. The deal positions Laurus Labs to compete more effectively against established players by localizing high-tech R&D in North America.
Operators in the biotechnology space should watch for increased competition in oligonucleotide development as these manufacturing synergies take hold. Suppliers and partners should track whether this infrastructure integration leads to reduced lead times or expanded service capabilities in the coming fiscal year.
The takeaway
The move signals that CDMOs are increasingly prioritizing the acquisition of niche, high-tech genetic technology firms to secure market share. Operators should evaluate their current dependency on third-party oligonucleotide providers and consider how changing manufacturing capacities might impact future vendor selection.
Further reading
For broader trends on shifts in industry manufacturing, visit our Healthcare section.
Live Poll
Do you believe large pharmaceutical companies acquiring smaller biotech startups benefits the healthcare market?
